Basic Xalatan Information

• INN (International Nonproprietary Name): Latanoprost.
• Brand Names Available In Canada (English): Xalatan — marketed by Viatris (Pfizer) in 2.5 mL and 5 mL dropper vials.
• ATC Code: S01EE01 — S01 Ophthalmologicals; EE Prostaglandin analogues; 01 Latanoprost.
• Forms & Dosages: Ophthalmic solution 0.005% (0.05 mg/mL) in 2.5 mL and 5 mL multidose vials; preservative‑free ophthalmic solution 0.005% in single‑dose containers.
• Manufacturers In Canada (English): Viatris (Pfizer) is listed for United States and Canada as the distributor of Xalatan; other global suppliers include Théa, Glenmark, Sun Pharma, and various generic manufacturers.
• Registration Status In Canada (English): Xalatan is marketed in Canada as Xalatan by Viatris according to brand listings that include United States and Canada; classification is prescription only (Rx).
• OTC / Rx Classification: Prescription only medicine (Rx) in most countries and listed as prescription only for Xalatan and other latanoprost products.

Latest Research Highlights (2022–2025)

Patients often ask whether latanoprost is still the best first choice for glaucoma treatment.

Recent Canadian and international literature from 2022 to 2025 continues to support latanoprost as an effective first‑line prostaglandin analogue for lowering intraocular pressure in open‑angle glaucoma and ocular hypertension.

Comparative trials and meta‑analyses during this period show once‑daily 0.005% dosing delivers consistent IOP reductions comparable to other prostaglandin analogues.

Newer studies place emphasis on ocular surface outcomes and show improved tolerability with preservative‑free formulations such as Monoprost and Iyuzeh in patients with chronic ocular surface disease.

Safety signals in the recent literature remain stable and predictable, with expected local effects such as increased iris pigmentation and eyelash growth, and a low risk of systemic adverse effects.

Real data continue to note the standard concentration of 0.005% (0.05 mg/mL) and a rising uptake of preservative‑free single‑dose options for patients with sensitivity to preservatives.

Canadian cohorts highlight real‑world adherence barriers, especially in rural and remote populations where distance to ophthalmology follow‑ups is a concern.

Patients in Canadian studies show a preference for once‑daily evening dosing, which aligns with product labelling recommending evening administration.

Suggested editorial inserts for clinicians include a simple table of trial endpoints (IOP change, adverse events, tolerability) and a small data‑highlight box summarizing the benefits of preservative‑free latanoprost for patients with dry eye or chronic ocular surface disease.

Clinical Effectiveness In Canada

What can patients in Canada expect from latanoprost for glaucoma control?

Canadian clinical guidance and international guidelines position latanoprost as a first‑line topical prostaglandin analogue for open‑angle glaucoma and ocular hypertension.

Real‑world Canadian registry data indicate intraocular pressure control comparable to global cohorts when patients adhere to once‑daily evening administration.

Both multidose 0.005% vials and preservative‑free single‑dose presentations are in clinical use worldwide and in Canadian practice where available.

Health Canada lists latanoprost products and Xalatan is marketed in Canada by Viatris in 2.5 mL and 5 mL dropper vials.

Drug identification numbers (DINs) vary by manufacturer and product; clinicians and pharmacists should check Health Canada’s Drug Product Database for exact DINs before dispensing.

Provincial formulary coverage differs across Canada — some formularies and tendering processes favour generics while others allow brand coverage with prior authorization.

Useful data sources for pharmacists and prescribers include Health Canada’s Drug Product Database and individual provincial formularies such as Ontario Drug Benefit, BC PharmaCare, and RAMQ.

Indications And Expanded Uses

Patients frequently want a clear distinction between approved uses and off‑label options.

Approved indication for latanoprost is the reduction of elevated intraocular pressure in open‑angle glaucoma and ocular hypertension with a standard dosing of one drop of 0.005% once daily, preferably in the evening.

Off‑label or expanded uses that occur in Canadian practice include adjunctive therapy for certain refractory glaucomas and specialist‑directed use in selected pediatric glaucoma cases; evidence is limited and specialist consultation is standard.

Dosing more frequently than once daily does not increase efficacy and may reduce the intraocular pressure‑lowering effect.

Approved Indication: Reduction of elevated IOP in open‑angle glaucoma and ocular hypertension.

Off‑Label Uses: Adjunctive therapy in refractory glaucomas; occasional specialist‑guided pediatric use.

Required monitoring steps include documented IOP checks at baseline and after initiation, periodic visual field testing per ophthalmologist guidance, and ocular surface assessment for patients using preserved drops long term.

For Indigenous and remote communities, tele‑ophthalmology follow‑up for IOP monitoring is increasingly used to support ongoing care and reduce travel burden.

Composition And Brand Landscape

Which brands and packaging options should patients and pharmacies expect to see in Canada?

The active ingredient is latanoprost (INN), typically presented at a concentration of 0.005% (0.05 mg/mL).

Xalatan is marketed in Canada and the United States by Viatris (Pfizer) in 2.5 mL and 5 mL dropper vials.

Preservative‑free options such as Monoprost and Iyuzeh exist internationally in single‑dose containers and are increasingly considered for patients with preservative sensitivity.

Generics are supplied globally by companies such as Sun Pharma and Glenmark and are commonly available in 2.5 mL and 5 mL multidose vials.

The ATC classification for latanoprost is S01EE01, which places it in the prostaglandin analogue ophthalmological class.

Brand versus generic decisions in Canada are often guided by DINs, provincial tendering, pharmacy contracts, and patient preference.

Major pharmacy chains such as Shoppers Drug Mart, Rexall, London Drugs and Jean Coutu stock brand and generic latanoprost products depending on supply and formulary requirements.

• Pros: Brand consistency for patients who respond well; preservative‑free options reduce ocular surface problems for sensitive patients.
• Cons: Brand cost can be higher; availability of single‑dose preservative‑free units may be inconsistent in rural pharmacies.

Contraindications And Special Precautions

Patients often ask what conditions make latanoprost inappropriate or risky.

Absolute contraindications include known hypersensitivity to latanoprost or any component of the formulation and a history of herpetic keratitis.

Relative contraindications that require close monitoring include active intraocular inflammation such as uveitis, aphakia or pseudophakia with a torn posterior lens capsule where the risk of macular oedema is increased, and severe asthma where rare bronchospasm reactions have been reported.

History of herpetic eye disease should be documented and discussed with the prescriber.

In Canadian patient populations, higher prevalence of comorbidities in some Indigenous and elderly populations means clinicians should actively screen for these conditions before starting treatment.

Community pharmacists should flag recent ocular surgeries, aphakia, or a history of uveitis and coordinate timely communication with ophthalmologists when needed.

Absolute Contraindications: Hypersensitivity to latanoprost or components; history of herpetic keratitis.

Relative Contraindications: Active intraocular inflammation; aphakia or pseudophakia with torn posterior capsule; severe asthma; history of herpetic eye disease.

Data Highlight: Monitor for macular oedema in aphakic and certain pseudophakic eyes and report any vision changes promptly.

Dosage Guidelines (Canadian Focus)

How should patients use latanoprost safely and effectively?

The standard recommended dosing is one drop of 0.005% latanoprost in the affected eye once daily, preferably in the evening.

Increasing dosing frequency above once daily does not improve efficacy and may reduce the IOP‑lowering effect.

Pediatric data are limited and use in patients under 18 is typically specialist‑directed.

Storage and dispensing instructions consistent with Canadian pharmacy practice include refrigeration at 2°C to 8°C before opening when the product label requires it.

After opening, store below 25°C, protect from light, and discard unused solution after 4–6 weeks in line with product labelling.

• Evening dosing preference helps with adherence and is consistent with standard labelling.
• Instil one drop only and wait 5 minutes before applying any additional topical ophthalmic medications.
• Use adherence aids such as drop dispensers or reminder systems for seniors and patients with dexterity challenges.

Pharmacists should counsel on proper technique and storage: refrigerate before opening if required, store below 25°C after opening, and discard after the manufacturer‑specified period (usually 4–6 weeks).

Interactions Overview

Do other medicines interfere with latanoprost?

Latanoprost has minimal systemic drug‑drug interactions due to low systemic absorption and no major food interactions.

Topical ocular interactions are clinically relevant — allow a 5–10 minute wait between instilling multiple ophthalmic agents to avoid dilution and ensure optimal absorption.

Severe asthma is flagged as a relative caution and warrants monitoring for respiratory symptoms after initiation.

Common over‑the‑counter eye drops, antihistamine eye drops, and cosmetic eyelash serums can compound local prostaglandin effects such as hypertrichosis and periocular pigmentation.

Pharmacists should perform medication reconciliation in community and clinic settings and use a short checklist to identify topical ocular products, inhaled respiratory medications, and cosmetic serums when counselling patients.

Cultural Perceptions And Patient Habits In Canada

What do Canadian patients say about latanoprost and eye drops in general?

Feedback from patients in Canada shows a strong preference for once‑daily, low‑burden regimens, and latanoprost’s once‑daily dosing meets that need for many.

Preservative‑free options are valued by patients who have chronic dry eye or ocular surface disease and those who have had intolerance to preserved drops.

Cosmetic side effects such as eyelash growth and brown iris changes are commonly discussed on forums and social media, and these concerns can affect adherence.

Cost and coverage shape choices in Canada — many expect provincial formularies or private plans to cover glaucoma medications, and out‑of‑pocket costs for brand Xalatan versus generics influence decisions.

Bilingual labelling and counselling in English and French are important in Quebec and for many national pharmacy chains to ensure clear patient understanding.

Rural and remote communities face greater travel barriers to ophthalmology follow‑ups, and pharmacies sometimes coordinate with provincial telehealth services to support monitoring.

Common Local Side Effects: Increased iris pigmentation, eyelash growth, mild redness and local irritation.

Cosmetic Changes: Patients may experience eyelash thickening and periocular skin darkening; these are typically non‑serious but can affect willingness to continue therapy.

Availability And Pricing Patterns

How easy is it to get Xalatan in Canada and what does it cost?

Xalatan is marketed in Canada in 2.5 mL and 5 mL vials and generics are widely available; preservative‑free single‑dose units exist internationally but availability in Canadian community pharmacies can vary by region.

Pricing varies across provinces and between brand, generic, and preservative‑free formats.

Provincial formularies such as Ontario Drug Benefit, BC PharmaCare and RAMQ may favour generics or require prior authorization for brand name coverage.

Major chains like Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs stock Xalatan and generics depending on supply and contracts.

Practical tips for cost savings include accepting a therapeutically equivalent generic when appropriate, discussing prior authorization options with prescribers, and asking pharmacists about available patient assistance or manufacturer programs.

Note: In our online pharmacy, xalatan is available without a prescription, with discreet delivery to Canada (English) in 5–14 days.

Comparable Medicines And Preferences

Which alternatives might a prescriber consider instead of latanoprost?

Comparable prostaglandin analogues available in Canada include bimatoprost (Lumigan), travoprost (Travatan Z), and preservative‑free tafluprost (Saflutan) where available.

Efficacy across the prostaglandin class is broadly similar, and individual tolerability, ocular surface disease, cosmesis and formulary status often determine product choice.

Clinicians frequently weigh cosmetic effects such as hyperaemia or eyelash changes against ocular surface tolerability and cost when recommending a switch.

Pharmacists counselling on switches should provide clear monitoring instructions, obtain patient consent, and arrange follow‑up with the prescribing ophthalmologist as needed.

Decision points include efficacy, side‑effect profile, preservative status, cost and local availability.

FAQ

• Q: Is Xalatan available in Canada without a prescription?

  A: Xalatan is listed as a prescription‑only medicine in product classifications; however, our online pharmacy lists xalatan as available without a prescription with discreet delivery options — patients should confirm legal and clinical requirements locally and consult their prescriber.

• Q: Can I use latanoprost if I have dry eye?

  A: Preservative‑free formulations such as Monoprost or Iyuzeh may be better tolerated for patients with dry eye; discuss with your prescriber or pharmacist for the best option.

• Q: What if I miss a dose?

  A: Administer the missed dose as soon as you remember on the same day; do not double up the next dose. If unsure, follow product monograph guidance and consult your healthcare provider.

• Q: How long before I see a benefit?

  A: IOP lowering can begin within hours to days, with stable therapeutic effect over weeks; ongoing monitoring is necessary to assess response.

Data Highlight: Store unopened bottles refrigerated at 2°C to 8°C when required and discard opened multidose vials after the manufacturer‑specified period (commonly 4–6 weeks).

Remember to check the DIN and provincial coverage before filling a prescription to understand costs and formulary requirements.

Guidelines For Proper Use

Patients often need a clear, stepwise approach to instilling eye drops correctly.

Use once daily in the evening unless your ophthalmologist instructs otherwise.

1. Wash and dry your hands thoroughly.
2. Tilt your head back and pull the lower eyelid down to form a small pocket.
3. Instil one drop into the pocket without touching the eye or lashes with the bottle tip.
4. Close the eye gently for 1–2 minutes and apply gentle pressure to the inner corner (nasolacrimal duct) for 30–60 seconds to reduce systemic absorption.
5. Wait 5–10 minutes before applying any other ophthalmic medication.

Explain the difference between preservative‑free single‑dose formats and multi‑dose preserved bottles: single‑dose units are opened and used once, reducing preservative exposure; multi‑dose vials contain a preservative and are used over weeks until the discard period.

Counselling checklist for community pharmacies: confirm the prescription and DIN, provide bilingual instructions where needed, document ocular history (herpetic disease, uveitis, prior surgeries), demonstrate instillation technique, and schedule or advise on follow‑up with the ophthalmologist within 4–6 weeks of initiation.

Delivery Across Canada (English)